William Blair initiated coverage of Audentes Therapeutics (NASDAQ:BOLD) with an “outperform” rating and $35 fair value estimate. The stock closed at $25 on Oct. 16.Read More
William Blair upgraded Sientra (NASDAQ:SIEN) to “outperform” from “market perform,” saying the company’s corporate strategy should begin to pay off over the next six-to-18 months.Read More
William Blair launched coverage of Biohaven Pharmaceutical Holding (NYSE:BHVN) with an “outperform” rating and fair value estimate of $46. The stock closed at $23.79 on May 26.Read More
William Blair initiated coverage of Albany Molecular Research (NASDAQ:AMRI) with an “outperform” rating. The stock closed at $17.31 on May 19.Read More
William Blair launched coverage of Akari Therapeutics (NASDAQ:AKTX) with an “outperform” rating. The stock closed at $11.62 on April 5.Read More
William Blair downgraded Arrowhead Pharmaceuticals (NASDAQ:ARWR) to “market perform” from “outperform” and slashed its price target to $2 from $12. The stock closed at $4.39 on Tuesday.Read More
William Blair raised its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $12 from $9 after the company licensed exclusive worldwide rights to two preclinical cardiovascular programs to Amgen (NASDAQ:AMGN).
Under the accord, Arrowhead would receive an up-front fee of $35-million and $21.5-million in equity, and up to $617-million in options and milestones, plus royalties.Read More
William Blair dropped coverage of OncoGenex (NASDAQ:OGXI) after the company announced that the AFFINITY study did not meet the primary endpoint. The stock closed at 90 cents on Monday.
“We note that AFFINITY is the key study of the lead asset, custirsen, as a chemotherapy companion in the second-line chemo setting in metastatic castration resistant prostate cancer,” writes analyst Katherine Xu.Read More
William Blair downgraded EndoChoice Holdings (NYSE:GI) to “market perform,” citing lower-than-expected second quarter results and reduced guidance. The stock closed at $5.26 on Wednesday.Read More
William Blair lowered its price target for Synthetic Biologics (NYSE:SYN) to $7 from $10, citing potential delays to commercialize the company’s two programs. The stock closed at $1.67 on Wednesday.Read More
William Blair has raised it price target for ARIAD Pharmaceuticals (NASDAQ:ARIA) to $12 from $10 after an analyst day on Friday where the company discussed the outcome of its strategic review. The stock was quoted at $7.59 on Monday afternoon.
The strategic review included ARIAD’s commitment to financial discipline and its refined focus on rare cancers with precision medicines in Iclusig, brigatinib, and AP32788, as well as discovery work on a suite of oral agents in immuno-oncology.Read More
William Blair & Co. has initiated coverage of Collegium Pharmaceutical (NASDAQ:COLL) with an “outperform” rating and price target of $35. The stock closed at $19.25 on Thursday.
Collegium’s lead product, Xtampza ER, an extended-release oxycodone-based product with abuse-deterrent technology (ADT), has received tentative approval from the FDA for the treatment of chronic pain that requires around-the-clock opioid analgesia for an extended period.Read More